April 23, 2020 -- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics to combat the novel coronavirus.
Integral Molecular will use its Shotgun Mutagenesis Epitope Mapping platform to identify the best antibody candidates to help develop an improved COVID-19 vaccine. The company will also utilize its Membrane Proteome Array platform to identify proteins that allow the novel coronavirus to invade cells. The system has been deployed on other epidemics, including the Zika, Ebola, and Chikungunya viruses.